Analyst firms · Guggenheim · CRL
Guggenheim CRL price target and rating history
Charles River Laboratories International Inc. (CRL) · Health Care
Guggenheim rates Charles River Laboratories International Inc. (CRL) Neutral with a $255 price target, as of its latest action on Feb 15, 2024. It has published 3 rating actions on CRL since May 2022, including 1 upgrade and 1 downgrade. Across 5 firms with a CRL price target in the last 12 months, the median target is $220.
- Current rating
- Neutral
- Price target
- $255
- Median target, all firms
- $220
- Actions on CRL
- 3
Every Guggenheim rating on CRL
- Feb 15, 2024
- Feb 23, 2023
- May 24, 2022
How other firms rate CRL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $357 | Sep 30, 2026 |
| CLSA | Hold | $219 | Jul 20, 2026 |
| Morgan Stanley | Overweight | $220 | Jun 17, 2026 |
| RBC Capital Markets | Outperform | $215 | Apr 14, 2026 |
| BofA Securities | Buy | $225 | Dec 15, 2025 |
| Argus Research | Buy | Nov 17, 2025 |
Questions about Guggenheim and CRL
- What is Guggenheim's price target for CRL?
- Guggenheim's latest stated price target for Charles River Laboratories International Inc. (CRL) is $255, from its action on Feb 23, 2023.
- What is Guggenheim's rating on CRL?
- Guggenheim rates CRL Neutral, a neutral rating, as of Feb 15, 2024.
- When did Guggenheim last change its view on CRL?
- On Feb 15, 2024, Guggenheim downgrades to Neutral from Buy.
- How does Guggenheim's CRL target compare with other analysts?
- Across 5 firms with a CRL price target in the last 12 months, the median target is $220.
More CRL rating histories
All Guggenheim ratingsCRL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.